Chimerix, Inc. Profile Avatar - Palmy Investing

Chimerix, Inc.

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is …

Biotechnology
US, Durham [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
Chimerix, Inc. can't present any analysts estimates at the moment detail analysis.
End of CMRX's Analysis
CIK: 1117480 CUSIP: 16934W106 ISIN: US16934W1062 LEI: - UEI: -
Secondary Listings
CMRX has no secondary listings inside our databases.